Antibodies IgG1 and IgG3 are related to complement fixation, antibody-dependent cellular toxicity, and viral neutralization41, and a recent study has demonstrated that IgG1 and IgG3 specific to RBD occurs primarily in COVID-19 patients during acute infection. This evidence concerns the gene IGHG3 and COVID-19.